These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32214401)

  • 1. Prognostic significance of inflammatory indices in hepatocellular carcinoma treated with transarterial chemoembolization: A systematic review and meta-analysis.
    Li S; Feng X; Cao G; Wang Q; Wang L
    PLoS One; 2020; 15(3):e0230879. PubMed ID: 32214401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis.
    Tian X; Dai Y; Wang DQ; Zhang L; Sui CG; Meng FD; Jiang SY; Liu YP; Jiang YH
    Drug Des Devel Ther; 2015; 9():4431-40. PubMed ID: 26309396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis.
    Qi X; Liu L; Wang D; Li H; Su C; Guo X
    Oncotarget; 2015 Nov; 6(34):36838-59. PubMed ID: 26451613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization.
    Fan W; Zhang Y; Wang Y; Yao X; Yang J; Li J
    PLoS One; 2015; 10(3):e0119312. PubMed ID: 25742141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis.
    Xiao WK; Chen D; Li SQ; Fu SJ; Peng BG; Liang LJ
    BMC Cancer; 2014 Feb; 14():117. PubMed ID: 24559042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
    He CB; Lin XJ
    PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as Prognostic Predictors for Hepatocellular Carcinoma Patients with Various Treatments: a Meta-Analysis and Systematic Review.
    Zheng J; Cai J; Li H; Zeng K; He L; Fu H; Zhang J; Chen L; Yao J; Zhang Y; Yang Y
    Cell Physiol Biochem; 2017; 44(3):967-981. PubMed ID: 29179180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does postoperative adjuvant transarterial chemoembolization benefit for all patients with hepatocellular carcinoma combined with microvascular invasion: a meta-analysis.
    Wang L; Ke Q; Lin N; Zeng Y; Liu J
    Scand J Gastroenterol; 2019 May; 54(5):528-537. PubMed ID: 31081401
    [No Abstract]   [Full Text] [Related]  

  • 9. Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma.
    Kim SS; Nam JS; Cho HJ; Won JH; Kim JW; Ji JH; Yang MJ; Park JH; Noh CK; Shin SJ; Lee KM; Cho SW; Cheong JY
    J Gastroenterol Hepatol; 2017 Jan; 32(1):199-207. PubMed ID: 27194671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Size Affects Efficacy of Adjuvant Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Microvascular Invasion.
    Liu S; Li H; Guo L; Zhang B; Zhou B; Zhang W; Zhou J; Fan J; Ye Q
    Oncologist; 2019 Apr; 24(4):513-520. PubMed ID: 30552155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of transarterial chemoembolization combined with microwave ablation for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Wang L; Ke Q; Lin N; Huang Q; Zeng Y; Liu J
    Int J Hyperthermia; 2019; 36(1):1288-1296. PubMed ID: 31852267
    [No Abstract]   [Full Text] [Related]  

  • 12. Radiomics as a tool for prognostic prediction in transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.
    Deng K; Chen T; Leng Z; Yang F; Lu T; Cao J; Pan W; Zheng Y
    Radiol Med; 2024 Aug; 129(8):1099-1117. PubMed ID: 39060885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-8 level as a prognostic marker in patients with hepatitis B virus-associated hepatocellular carcinoma treated with transarterial chemoembolization.
    Kim SS; Cho HJ; Won JH; Bae JI; Kang DR; Lee JD; Shin SJ; Lee KM; Yoo BM; Kim JK; Lee JH; Ahn SJ; Park JH; Cho SW; Cheong JY
    Cytokine; 2015 Dec; 76(2):449-457. PubMed ID: 26163999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
    Zhang XP; Wang K; Li N; Zhong CQ; Wei XB; Cheng YQ; Gao YZ; Wang H; Cheng SQ
    BMC Cancer; 2017 Dec; 17(1):902. PubMed ID: 29282010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
    Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
    Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic immune-inflammation index and the survival of hepatocellular carcinoma patients after transarterial chemoembolization: a meta-analysis.
    Li D; Zhao X; Pi X; Wang K; Song D
    Clin Exp Med; 2023 Oct; 23(6):2105-2114. PubMed ID: 36287310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
    BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
    Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials.
    Zeng J; Lv L; Mei ZC
    Clin Res Hepatol Gastroenterol; 2016 Dec; 40(6):688-697. PubMed ID: 27339594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pretransplant neutrophil-lymphocyte ratio as a new prognostic predictor after liver transplantation for hepatocellular cancer: a systematic review and meta-analysis.
    Xu ZG; Ye CJ; Liu LX; Wu G; Zhao ZX; Wang YZ; Shi BQ; Wang YH
    Biomark Med; 2018 Feb; 12(2):189-199. PubMed ID: 29327595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.